Expression of eukaryotic translation initiation factor 3 subunit B in liver cancer and its prognostic significance

Yue,Qing; Meng,Lingyu; Jia,Baoxing; Han,Wei

doi:10.3892/etm.2020.8726

Expression of eukaryotic translation initiation factor 3 subunit B in liver cancer and its prognostic significance

Authors:
- Qing Yue
- Lingyu Meng
- Baoxing Jia
- Wei Han
View Affiliations

Affiliations: Department of Oncology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: May 7, 2020 https://doi.org/10.3892/etm.2020.8726
Pages: 436-446
Copyright: © Yue et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Liver cancer is one of the major malignancies with the worst prognosis among all solid tumor types. It is therefore ponderable to explore prognostic biomarkers and therapeutic targets for liver cancer. Eukaryotic translation initiation factor 3 subunit B (EIF3B) is closely linked to the transcription initiation of cancer‑associated genes. In the present study, EIF3B was indicated to be a potential prognostic biomarker of liver cancer. The mRNA expression level of EIF3B in liver cancer was assessed by analyzing the Cancer Genome Atlas dataset. χ2 and Fisher's exact tests were used to assess the association of EIF3B expression with clinical parameters. Receiver‑operating characteristic curve analysis was used for evaluating the diagnostic value of EIF3B. Overall and relapse‑free survival were assessed using Kaplan‑Meier curves to determine the association between EIF3B expression and survival. Univariate and multivariate Cox regression analysis were performed to identify the factors affecting overall/relapse‑free survival. Gene set enrichment analysis (GSEA) was used to identify signaling pathways associated with EIF3B in liver cancer. It was revealed that EIF3B was highly expressed in liver cancer tissues and it had a promising diagnostic ability. Furthermore, the survival analysis indicated that patients with high EIF3B expression generally had shorter overall as well as relapse‑free survival. Univariate and multivariate Cox analysis suggested that high EIF3B mRNA expression may serve as an independent biomarker for the prognostication of patients with liver cancer. GSEA suggested that MYC‑V1 (HALLMARK_MYC_TARGETS_V1 geneset; P=0.009), MYC‑V2 (HALLMARK_MYC_TARGETS_V2 geneset; P=0.004) and DNA repair pathways (HALLMARK_DNA_REPAIR geneset; P<0.001) were differentially enriched in high EIF3B expression and low EIF3B expression groups. In conclusion, high EIF3B expression was indicated to be an independent prognostic biomarker for patients with liver cancer.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019.PubMed/NCBI View Article : Google Scholar
2	Ryerson AB, Eheman CR, Altekruse SF, Ward JW, Jemal A, Sherman RL, Henley SJ, Holtzman D, Lake A, Noone AM, et al: Annual Report to the Nation on the Status of Cancer, 1975-2012, Featuring the Increasing Incidence of Liver Cancer. Cancer. 122:1312–1337. 2016.PubMed/NCBI View Article : Google Scholar
3	Li L and Wang H: Heterogeneity of liver cancer and personalized therapy. Cancer Lett. 379:191–197. 2016.PubMed/NCBI View Article : Google Scholar
4	Dawkins J and Webster RM: The hepatocellular carcinoma market. Nat Rev Drug Discov. 18:13–14. 2019.PubMed/NCBI View Article : Google Scholar
5	Smith MD, Arake-Tacca L, Nitido A, Montabana E, Park A and Cate JH: Assembly of eIF3 mediated by mutually dependent subunit insertion. Structure. 24:886–896. 2016.PubMed/NCBI View Article : Google Scholar
6	Zang Y, Zhang X, Yan L, Gu G, Li D, Zhang Y, Fang L, Fu S, Ren J and Xu Z: Eukaryotic translation initiation factor 3b is both a promising prognostic biomarker and a potential therapeutic target for patients with clear cell renal cell carcinoma. J Cancer. 8:3049–3061. 2017.PubMed/NCBI View Article : Google Scholar
7	Xu F, Xu CZ, Gu J, Liu X, Liu R, Huang E, Yuan Y, Zhao G, Jiang J, Xu C, et al: Eukaryotic translation initiation factor 3B accelerates the progression of esophageal squamous cell carcinoma by activating β-catenin signaling pathway. Oncotarget. 7:43401–43411. 2016.PubMed/NCBI View Article : Google Scholar
8	Liang H, Ding X, Zhou C, Zhang Y, Xu M, Zhang C and Xu L: Knockdown of eukaryotic translation initiation factors 3B (EIF3B) inhibits proliferation and promotes apoptosis in glioblastoma cells. Neurol Sci. 33:1057–1062. 2012.PubMed/NCBI View Article : Google Scholar
9	Wang L and Ouyang L: Effects of EIF3B gene downregulation on apoptosis and proliferation of human ovarian cancer SKOV3 and HO-8910 cells. Biomed Pharmacother. 109:831–837. 2019.PubMed/NCBI View Article : Google Scholar
10	Choi YJ, Lee YS, Lee HW, Shim DM and Seo SW: Silencing of translation initiation factor eIF3b promotes apoptosis in osteosarcoma cells. Bone Joint Res. 6:186–193. 2017.PubMed/NCBI View Article : Google Scholar
11	Tian Y, Zhao K, Yuan L, Li J, Feng S, Feng Y, Fang Z, Li H and Deng R: EIF3B correlates with advanced disease stages and poor prognosis, and it promotes proliferation and inhibits apoptosis in non-small cell lung cancer. Cancer Biomark. 23:291–300. 2018.PubMed/NCBI View Article : Google Scholar
12	Spilka R, Ernst C, Mehta AK and Haybaeck J: Eukaryotic translation initiation factors in cancer development and progression. Cancer Lett. 340:9–21. 2013.PubMed/NCBI View Article : Google Scholar
13	Wang H, Ru Y, Sanchez-Carbayo M, Wang X, Kieft JS and Theodorescu D: Translation initiation factor eIF3b expression in human cancer and its role in tumor growth and lung colonization. Clin Cancer Res. 19:2850–2860. 2013.PubMed/NCBI View Article : Google Scholar
14	Lin L, Holbro T, Alonso G, Gerosa D and Burger MM: Molecular interaction between human tumor marker protein p150, the largest subunit of eIF3, and intermediate filament protein K7. J Cell Biochem. 80:483–490. 2001.PubMed/NCBI View Article : Google Scholar
15	Golob-Schwarzl N, Krassnig S, Toeglhofer AM, Park YN, Gogg-Kamerer M, Vierlinger K, Schröder F, Rhee H, Schicho R, Fickert P and Haybaeck J: New liver cancer biomarkers: PI3K/AKT/mTOR pathway members and eukaryotic translation initiation factors. Eur J Cancer. 83:56–70. 2017.PubMed/NCBI View Article : Google Scholar
16	Team RDCJCR. A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 14:12–21. 2009. View Article : Google Scholar
17	Wickham H: Ggplot2: Elegant graphics for data analysis. J R Stat Soc. 174:245–246. 2011.
18	Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC and Müller M: pROC: An open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 12(77)2011.PubMed/NCBI View Article : Google Scholar
19	Therneau TM and Grambsch PM: Modeling survival data: Extending the Cox model. Springer, New York, 2000.
20	Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005.PubMed/NCBI View Article : Google Scholar
21	Cronin KA, Lake AJ, Scott S, Sherman RL, Noone AM, Howlader N, Henley SJ, Anderson RN, Firth AU, Ma J, et al: Annual report to the nation on the status of cancer, part I: National cancer statistics. Cancer. 124:2785–2800. 2018.PubMed/NCBI View Article : Google Scholar
22	Xu N, Liu YN, Yin P, Wang LJ, Dou YS, Yang WJ and Zhou MG: Impact of liver cancer deaths on life expectancy in 14 counties (districts) from the Huai River Basin, 2013: Relationship between the water environment and liver cancer. Zhonghua Yu Fang Yi Xue Za Zhi. 50:629–633. 2016.PubMed/NCBI View Article : Google Scholar : (In Chinese).
23	Tu T, Bühler S and Bartenschlager R: Chronic viral hepatitis and its association with liver cancer. Biol Chem. 398:817–837. 2017.PubMed/NCBI View Article : Google Scholar
24	Chen YJ, Wallig MA and Jeffery EH: Dietary broccoli lessens development of fatty liver and liver cancer in mice given diethylnitrosamine and fed a western or control diet. J Nutr. 146:542–550. 2016.PubMed/NCBI View Article : Google Scholar
25	Global Burden of Disease Cancer Collaboration. Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, Allen C, Alsharif U, Alvis-Guzman N, Amini E, et al: Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: A systematic analysis for the global burden of disease study. JAMA Oncol. 4:1553–1568. 2018.PubMed/NCBI View Article : Google Scholar
26	Jiao Y, Fu Z, Li Y, Meng L and Liu Y: High EIF2B5 mRNA expression and its prognostic significance in liver cancer: A study based on the TCGA and GEO database. Cancer Manag Res. 10:6003–6014. 2018.PubMed/NCBI View Article : Google Scholar
27	Jiao Y, Fu Z, Li Y, Zhang W and Liu Y: Aberrant FAM64A mRNA expression is an independent predictor of poor survival in pancreatic cancer. PLoS One. 14(e0211291)2019.PubMed/NCBI View Article : Google Scholar
28	Jiao Y, Li Y, Lu Z and Liu Y: High trophinin-associated protein expression is an independent predictor of poor survival in liver cancer. Dig Dis Sci. 64:137–143. 2019.PubMed/NCBI View Article : Google Scholar
29	Jiao Y, Li Y, Fu Z, Hou L, Chen Q, Cai Y, Jiang P, He M and Yang Z: OGDHL expression as a prognostic biomarker for liver cancer patients. Dis Markers. 2019(9037131)2019.PubMed/NCBI View Article : Google Scholar
30	Jiao Y, Li Y, Jiang P, Han W and Liu Y: PGM5: A novel diagnostic and prognostic biomarker for liver cancer. PeerJ. 7(e7070)2019.PubMed/NCBI View Article : Google Scholar
31	Jiao Y, Li Y, Liu S, Chen Q and Liu Y: ITGA3 serves as a diagnostic and prognostic biomarker for pancreatic cancer. Onco Targets Ther. 12:4141–4152. 2019.PubMed/NCBI View Article : Google Scholar
32	Li Y, Jiao Y, Fu Z, Luo Z, Su J and Li Y: High miR-454-3p expression predicts poor prognosis in hepatocellular carcinoma. Cancer Manag Res. 11:2795–2802. 2019.PubMed/NCBI View Article : Google Scholar
33	Li Y, Jiao Y, Li Y and Liu Y: Expression of La ribonucleoprotein domain family member 4B (LARP4B) in liver cancer and their clinical and prognostic significance. Dis Markers. 2019(1569049)2019.PubMed/NCBI View Article : Google Scholar
34	Li Y, Jiao Y, Luo Z, Li Y and Liu Y: High peroxidasin-like expression is a potential and independent prognostic biomarker in breast cancer. Medicine (Baltimore). 98(e17703)2019.PubMed/NCBI View Article : Google Scholar
35	Zhang X, Cui Y, He M, Jiao Y and Yang Z: Lipocalin-1 expression as a prognosticator marker of survival in breast cancer patients. Breast Care, 2019.
36	Cui Y, Jiao Y, Wang K, He M and Yang Z: A new prognostic factor of breast cancer: High carboxyl ester lipase expression related to poor survival. Cancer Genet. 239:54–61. 2019.PubMed/NCBI View Article : Google Scholar
37	Hou L, Zhang X, Jiao Y, Li Y, Zhao Y, Guan Y and Liu Z: ATP binding cassette subfamily B member 9 (ABCB9) is a prognostic indicator of overall survival in ovarian cancer. Medicine (Baltimore). 98(e15698)2019.PubMed/NCBI View Article : Google Scholar
38	Cai H, Jiao Y, Li Y, Yang Z, He M and Liu Y: Low CYp24A1 mRNA expression and its role in prognosis of breast cancer. Sci Rep. 9(13714)2019.PubMed/NCBI View Article : Google Scholar
39	Ma F, Li X, Ren J, Guo R, Li Y, Liu J, Sun Y, Liu Z, Jia J and Li W: Downregulation of eukaryotic translation initiation factor 3b inhibited proliferation and metastasis of gastric cancer. Cell Death Dis. 10(623)2019.PubMed/NCBI View Article : Google Scholar
40	Ladu S, Calvisi DF, Conner EA, Farina M, Factor VM and Thorgeirsson SS: E2F1 inhibits c-Myc-driven apoptosis via pIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer. Gastroenterology. 135:1322–1332. 2008.PubMed/NCBI View Article : Google Scholar
41	Xin B, Yamamoto M, Fujii K, Ooshio T, Chen X, Okada Y, Watanabe K, Miyokawa N, Furukawa H and Nishikawa Y: Critical role of Myc activation in mouse hepatocarcinogenesis induced by the activation of AKT and RAS pathways. Oncogene. 36:5087–5097. 2017.PubMed/NCBI View Article : Google Scholar
42	Li X, Wu Q, Bu M, Hu L, Du WW, Jiao C, Pan H, Sdiri M, Wu N, Xie Y and Yang BB: Ergosterol peroxide activates Foxo3-mediated cell death signaling by inhibiting AKT and c-Myc in human hepatocellular carcinoma cells. Oncotarget. 7:33948–33959. 2016.PubMed/NCBI View Article : Google Scholar
43	Barnes JL, Zubair M, John K, Poirier MC and Martin FL: Carcinogens and DNA damage. Biochem Soc Trans. 46:1213–1224. 2018.PubMed/NCBI View Article : Google Scholar